About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

By: StockStory

VRTX Cover Image

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of Wall Street expectations, leading to a significant negative market reaction. Management attributed the subdued performance to factors including slower-than-anticipated uptake for newly launched products and specific regional pressures, such as a decline in ex-U.S. cystic fibrosis (CF) revenues due to market dynamics in Russia. CEO Reshma Kewalramani acknowledged, “Russia revenue was negatively impacted by the availability of an illegal copy product,” resulting in a notable headwind for the quarter. Increased research, development, and commercial spending—particularly for pain and kidney disease programs—also weighed on operating margins.

Is now the time to buy VRTX? Find out in our full research report (it’s free).

Vertex Pharmaceuticals (VRTX) Q1 CY2025 Highlights:

  • Revenue: $2.77 billion vs analyst estimates of $2.83 billion (3% year-on-year growth, 2.3% miss)
  • Adjusted EPS: $4.06 vs analyst expectations of $4.29 (5.4% miss)
  • Adjusted EBITDA: $1.23 billion vs analyst estimates of $1.31 billion (44.5% margin, 6.2% miss)
  • The company reconfirmed its revenue guidance for the full year of $11.88 billion at the midpoint
  • Operating Margin: 22.7%, down from 42.4% in the same quarter last year
  • Market Capitalization: $114.5 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Vertex Pharmaceuticals’s Q1 Earnings Call

  • Geoffrey Meacham (Citibank) asked if the ALYFTREK launch was driven more by dosing convenience or clinical biomarkers. Chief Commercial Officer Stuart Arbuckle replied that uptake is due to a combination of noninferiority to existing therapies, improved CFTR function, expanded mutation coverage, and once-daily dosing.

  • Jessica Fye (JPMorgan) questioned exposure to tariffs and the impact of the Russia market. CFO Charles Wagner clarified that Vertex’s supply chain has minimal exposure to China, with most CF drug manufacturing and intellectual property based in the U.S. and U.K., and that the Russian revenue impact is isolated and already included in guidance.

  • Salveen Richter (Goldman Sachs) probed early patient segments for ALYFTREK and payer coverage for JOURNAVX. Arbuckle confirmed fastest uptake among newly eligible patients, while McKechnie emphasized ongoing efforts to secure broad, low-restriction coverage and optimize long-term value for the company.

  • Tazeen Ahmad (BofA Merrill Lynch) inquired about the settings and patient profiles for JOURNAVX prescriptions. Duncan McKechnie explained that the medication is being adopted for both surgical and non-surgical acute pain across various specialties, with early use concentrated in discharge settings, and noted that initial volumes will precede significant revenue as payer coverage ramps.

  • Evan Seigerman (BMO Capital Markets) asked about hurdles to CASGEVY adoption. Arbuckle identified the need for more authorized treatment centers, payer coverage, and increased familiarity among treatment centers with the complex therapy process as key factors influencing uptake.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace of patient transitions to ALYFTREK, especially as regulatory approvals expand globally, (2) the ramp-up in JOURNAVX revenue as payer coverage and hospital formulary access broaden, and (3) progress on pivotal clinical trials in pain, diabetes, and kidney disease. Execution on these fronts, as well as the ability to control operating expenses, will be important indicators of Vertex’s ability to deliver on its growth strategy.

Vertex Pharmaceuticals currently trades at $443.40, down from $499.76 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

More News

View More
3 Defense Stocks Surging as Ukraine Tensions Deepen
Via MarketBeat
Topics Government
Tickers BAESY RNMBY SAABY
Starbucks Stock Slumps; This Competitor Shows Strength
Via MarketBeat
Tickers BROS SBUX
The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Via MarketBeat
Tickers AMZN GOOG GOOGL TTD
Are Airline Stocks Ready for Takeoff After a Turbulent 2025?
Via MarketBeat
Topics Economy
Tickers AAL DAL LUV XTN
Why the Precious Metal Nobody Talks About Could Be Your Best Bet
Via MarketBeat
Topics ETFs Economy
Tickers PALL VOO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.